BioAsia: The Global Biobusiness Forum

BioAsia: The Global Biobusiness Forum BioAsia 2026; TechBio Unleashed: AI, Automation & The Biology Revolution. The 17th BioAsia scheduled to be held from Feb 17-19, 2020 in Hyderabad.

This edition brings the world’s focus to the cutting-edge innovations redefining global health across biopharmaceuticals, digital health, medical devices, and advanced therapeutics. BioAsia seeks to encourage newer innovations, path-breaking discoveries and effective solutions in the Biotechnology industry with an objective of optimizing the immense business potential of biotech. It revolves aroun

d the theme "Today for Tomorrow"

Globally, the rise of more informed healthcare consumers, new technologies, and ubiquity of data and analytics continues to blur the traditional boundaries between therapeutics, medical technologies, consumer devices and information technology (IT). This rapidly evolving superfluid market is putting pressure on the life sciences (LS) companies to change their business models and personalize their products and services. The question life sciences companies must address urgently is how they should be preparing themselves for the coming future. BioAsia 2020 explores the capabilities that Life sciences companies should invest in Today to thrive and create value Tomorrow.

18/02/2026

Global collaboration and future-focused healthcare innovation took centre stage at BioAsia 2026, where Barnabe Delarze from Swissnex spoke about the vast potential of India as a rapidly expanding life sciences market. He underlined the opportunity to address metabolic diseases through digital innovation, highlighting alternate, behaviour-driven approaches that target disease at its root, pointing toward a future where technology-enabled preventive healthcare can work alongside or reduce reliance on traditional drug-based treatments.

18/02/2026

At BioAsia 2026, industry voices like Shylender Bijapur and Patrick Morsch reflected on the growing global confidence in India as an emerging pharmaceutical and life sciences powerhouse. Their perspective reinforces how the country’s deep talent pool, expanding research ecosystem, and accelerating innovation momentum are positioning it as a key destination shaping the future of global healthcare and pharmaceutical advancement.

18/02/2026

Powering the future of breakthrough science and manufacturing, BioAsia 2026 featured Financing TechBio & DeepTech Manufacturing, bringing together leading investor perspectives on scaling high-impact innovation. The session included insights from Mr. Ajay Mahipal, Mr. Karthik Narayanaswamy, Mr. Sunil Thakur, and Dr. Ramesh Byrappaneni, and was moderated by Mr. Atin Tomar. Discussions highlighted how investors evaluate risk in deep tech and advanced biotech, strategies to de-risk innovation, and the growing opportunity to scale breakthrough technologies from India to the global stage.

18/02/2026

At BioAsia 2026, India’s Innovation Moment: Scaling the Next Phase of Global Impact brought together leading voices across research, industry, and global business to examine India’s fast-evolving innovation landscape. The session featured insights from Dr. Jitendra Kumar, Dr. Murali Ramachandra, Mr. Sridhar Gopal, Mr. Nataraj Kalyanaraman, Mr. Sanjeev Sachdeva, Mr. Raja Jammalamadaka, and Mr. Greg Killian, and was moderated by Mr. Vikas Dandekar. Discussions highlighted India’s rapid innovation growth, while addressing critical challenges across funding, talent, and commercialization needed to accelerate global impact at scale.

From policy to research, from innovation to real-world healthcare impact, our esteemed dignitaries share powerful perspe...
18/02/2026

From policy to research, from innovation to real-world healthcare impact, our esteemed dignitaries share powerful perspectives at BioAsia 2026, reflecting a shared commitment to advancing global health through collaboration and science-led progress.

Marking a significant moment for the life sciences ecosystem, Sri D. Sridhar Babu, Hon’ble Minister for Industries and C...
18/02/2026

Marking a significant moment for the life sciences ecosystem, Sri D. Sridhar Babu, Hon’ble Minister for Industries and Commerce, Government of Telangana, attended the inauguration of BioAsia 2026. During his address, he reaffirmed Hyderabad’s global leadership in vaccine manufacturing, highlighting its recognition as the Vaccine Capital of the World and its growing role in shaping the future of global healthcare and life sciences innovation.

18/02/2026

Shaping healthcare outcomes where it matters most, Making It Matter: How GCCs Transform Capability into End-Patient Impact brought together global perspectives at Bio Asia 2026 under the moderation of Ms. Shalini Pillay. Panelists Mr. Siva Kumar Padmanabhan, Ms. Esha Juneja, Dr. Anand Jain, Mr. Manish Arora, Mr. Mahesh Natarajan and Mr. Srinivas Peddi discussed ageing demographics, critical patient pricing, cross-border complexities, and embedding AI at the core of GCC transformation. The session, led in collaboration with KPMG, also marked the release of a whitepaper capturing real-world patient impact stories from healthcare GCCs.

18/02/2026

At BioAsia 2026, Swati Rathor from Sai Life Sciences reflected the strength of the BioAsia platform in bringing together global pharma, biotech, and life sciences stakeholders. BioAsia continues to serve as a key hub for industry engagement, collaboration, and ecosystem growth, reinforcing its role in advancing innovation, partnerships, and the future of healthcare and life sciences.

Marking a significant moment for the life sciences ecosystem, Sri D. Sridhar Babu, Hon’ble Minister for Industries and C...
18/02/2026

Marking a significant moment for the life sciences ecosystem, Sri D. Sridhar Babu, Hon’ble Minister for Industries and Commerce, Government of Telangana, attended the inauguration of BioAsia 2026. During his address, he reaffirmed Hyderabad’s global leadership in vaccine manufacturing, highlighting its recognition as the Vaccine Capital of the World and its growing role in shaping the future of global healthcare and life sciences innovation.

18/02/2026

At BioAsia 2026, the panel discussion on Building Innovation-First GCCs: AI, R&D & Digital Transformation set the tone for how global capability centers are evolving into innovation powerhouses. The session opened with a keynote by Mr. Anton Groom, followed by a dynamic discussion moderated by Dr. Purav Gandhi, featuring insights from Mr. Badhri Srinivasan, Mr. Syed Naveed, Mr. Sanjay Patel, Mr. Som Chattopadhyay, and Ms. Gail Horwood. The conversation focused on how AI-led transformation, integrated R&D strategies, and digital-first operating models are enabling GCCs to move beyond support functions to become drivers of enterprise-wide innovation and long-term value creation.

18/02/2026

At BioAsia 2026, Ms. Madeline Roach (EVP, Head of Business Operations, Sanofi, France) spotlighted the real impact of AI in healthcare, from strengthening governance frameworks and improving accountability for outcomes, to enabling smarter resource allocation and reducing program delivery costs. Reinforcing a future-ready mindset, she shared a powerful perspective: AI will not replace humans, but humans with AI will replace humans without AI

Address

301, Gayathri Nest, Telecom Nagar
Hyderabad
500032

Telephone

+914023000205

Website

Alerts

Be the first to know and let us send you an email when BioAsia: The Global Biobusiness Forum posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to BioAsia: The Global Biobusiness Forum:

Shortcuts

Share

Category